Dr Charlie Easmon from Your Excellent Health Service gives a medical professional’s opinion on medical marijuana in the UK, including comment on hemp, CBD and THC.
Here, Robin Emerson, Head of CSR at Brains Bioceutical charts the priorities for cannabis research.
Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.
Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.
Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.
OCD symptoms could be eased by atleast half in the short-term, according to a new study published in the Journal of Affective Disorders.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.
In early 2016, I had reached a point in life where I needed to make a life-changing decision: Read the Savage Cabbage journey on OAG.
Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.
Hannah Deacon, co-founder of Maple Tree Consultancy, explores how COVID is elevating and shaping the medical application of CBD.
Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.
A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.
Professor Tilmann Weber discusses how microbial genomics helps to find the next generation of antibiotics in the race against antimicrobial resistance.
Savage Cabbage Ltd offer their expertise to explain what cannabidiol (CBD) is and how it works: Read on to find out their perspective.